Book Review
Cancer Prevention and Control
N Engl J Med 1995; 333:673September 7, 1995
- Article
Cancer Prevention and Control
(Basic and Clinical Oncology.) Edited by Peter Greenwald, Barnett S. Kramer, and Douglas L. Weed. 803 pp. New York, Marcel Dekker, 1995. $195. ISBN: 0-8247-9258-0The field of cancer prevention and control includes a broad range of related ideas, methods, and activities; its practitioners, researchers, and teachers come from many disciplines. Its scientific basis is being advanced by increasingly sophisticated analytic techniques. Much greater understanding exists now than ever before of the nature of carcinogenesis and the respective contributions of inherited and environmental factors. As preventive interventions are tested, validated, and introduced into routine clinical practice, psychosocial, ethical, and economic issues are being studied.
Historically, the passage of the National Cancer Act in 1971, the creation of the Division of Cancer Control and Rehabilitation in 1974, and the establishment in 1983 of the Division of Cancer Prevention and Control were critical events in the evolution of cancer prevention in the United States. Dr. Greenwald defines cancer control in his introduction as “the reduction of cancer incidence, morbidity and mortality through an orderly sequence from research on interventions and their impact in defined populations to the broad, systematic application of the research results.” The application on a broad scale of these concepts, as well as a rigorous application of the scientific method in cancer-prevention research, has had substantial and far-reaching effects not only in the United States but also abroad.
It is perhaps most fitting that the editors of this book are senior scientists at the National Cancer Institute. This comprehensive, multiauthored book has six sections. Part I, “The Burden of Cancer,” describes the magnitude of cancer in the United States and internationally. This section gives a detailed analysis of the economic aspects of cancer. Part II, “Basic Concepts in the Biology of Cancer,” describes carcinogenesis, risk assessment, biomarkers, and genetic–environmental interactions. Part III, “The Methodologies of Cancer Prevention Research,” emphasizes research strategies and trial design. In part IV, “The Practice of Cancer Prevention and Control,” dietary prevention, chemoprevention, control of tobacco use, and legal and ethical aspects are described and evaluated. Part V, “Prevention and Control for Organ-Specific Tumors,” presents practical information on specific approaches to the prevention of cancers of individual organs, such as breast, lung, skin, head and neck, and large-bowel cancers. In part VI, “The Future of Cancer Research and Control,” contributors discuss future developments in cancer prevention, including the use of models and training in cancer prevention. The appendixes contain useful information such as state-of-the-art statements on cancer screening from the National Cancer Institute. My only substantive criticism concerns the absence of a chapter describing the methodologic aspects and accomplishments of behavioral-science research as applied to primary prevention, screening, early detection, and quality-of-life assessment. One hopes that this lack will be remedied in subsequent editions.
The chapters, written by acknowledged experts from the United States, Canada, and Australia, are authoritative and well referenced with current (1994) bibliographic citations. The editors have successfully achieved considerable consistency of style in the construction of the chapters. Although emphases may shift as new concepts emerge, the book establishes a new standard of excellence for this emerging field. It is rendered even more useful by virtue of a detailed index.
Bernard Levin, M.D.
University of Texas M.D. Anderson Cancer Center, Houston, TX 77030- Citing Articles (35)
Citing Articles
1
Cândida A.L. Kassuya, Alexandre P. Rogerio, João B. Calixto. (2008) The role of ETA and ETB receptor antagonists in acute and allergic inflammation in mice. Peptides 29:8, 1329-1337
CrossRef2
Andrew Leask. (2008) Targeting the TGFβ, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cellular Signalling 20:8, 1409-1414
CrossRef3
Claudia Penna, Raffaella Rastaldo, Daniele Mancardi, Sandra Cappello, Pasquale Pagliaro, Nico Westerhof, Gianni Losano. (2006) Effect of endothelins on the cardiovascular system. Journal of Cardiovascular Medicine 7:9, 645-652
CrossRef4
Carsten Höltke, Marilyn P. Law, Stefan Wagner, Hans-Jörg Breyholz, Klaus Kopka, Christoph Bremer, Bodo Levkau, Otmar Schober, Michael Schäfers. (2006) Synthesis, in vitro pharmacology and biodistribution studies of new PD 156707-derived ETA receptor radioligands. Bioorganic & Medicinal Chemistry 14:6, 1910-1917
CrossRef5
Anna M. Hackman, Thomas E. Lackner. (2006) Pharmacotherapy for Idiopathic Pulmonary Arterial Hypertension During the Past 25 Years. Pharmacotherapy 26:1, 68-94
CrossRef6
Ignacio Gil-Ortega, Raquel Marzoa Rivas, Ramón Ríos Vázquez, Juan Carlos Kaski. (2006) Role of inflammation and endothelial dysfunction in the pathogenesis of cardiac syndrome X. Future Cardiology 2:1, 63-73
CrossRef7
Gysèle S. Bleumink, Anna F.C. Schut, Miriam C.J.M. Sturkenboom, Jaap W. Deckers, Cornelia M. van Duijn, Bruno H.Ch. Stricker. (2004) Genetic polymorphisms and heart failure. Genetics in Medicine 6:6, 465-474
CrossRef8
Yukio Suga, Hidesaku Asakura, Tomotaka Yoshida, Mika Omote, Yasuo Ontachi, Tomoe Mizutani, Masahide Yamazaki, Eriko Morishita, Shinji Nakao, Ken-ichi Miyamoto. (2004) Relationship between endothelin and the pathophysiology of tissue factor-induced and lipopolysaccharide-induced disseminated intravascular coagulation in rats. Blood Coagulation & Fibrinolysis 15:7, 593-598
CrossRef9
Yuji Hirai, Hisashi Adachi, Yoshihisa Fujiura, Akiko Hiratsuka, Mika Enomoto, Tsutomu Imaizumi. (2004) Plasma endothelin-1 level is related to renal function and smoking status but not to blood pressure. Journal of Hypertension 22:4, 713-718
CrossRef10
Shamsuddin Akhtar, Paul G. Barash. (2003) Perioperative Use of Beta-Blockers: Past, Present, and Future. International Anesthesiology Clinics 40:2, 133-157
CrossRef11
Judy W. M. Cheng. (2003) Bosentan. Heart Disease 5:2, 161-169
CrossRef12
Andrew T. Goodwin, Magdi H. Yacoub. (2001) Role of endogenous endothelin on coronary flow in health and disease. Coronary Artery Disease 12:6, 517-524
CrossRef13
Sukhdeep Kaur, William H. Frishman, Inderpal Singh, Praveen Tamirisa, Anil Kumar. (2001) Endothelin as a Therapeutic Target in the Treatment of Cardiovascular Disease. Heart Disease 3:3, 176-188
CrossRef14
Emi Arikawa, Subodh Verma, Aaron S. Dumont, John H. McNeill. (2001) Chronic bosentan treatment improves renal artery vascular function in diabetes. Journal of Hypertension 19:4, 803-812
CrossRef15
Jose E Tanus-Santos, Rita C Sampaio, Stephen Hyslop, Kleber G Franchini, Heitor Moreno. (2000) Endothelin ETA receptor antagonism attenuates the pressor effects of nicotine in rats. European Journal of Pharmacology 396:1, 33-37
CrossRef16
Debra L. Sherman. (2000) Exercise and endothelial function. Coronary Artery Disease 11:2, 117-122
CrossRef17
Pankaj Sharma, Aroon Hingorani, Haiyan Jia, Ruth Hopper, Morris J. Brown. (1999) Quantitative association between a newly identified molecular variant in the endothelin-2 gene and human essential hypertension. Journal of Hypertension 17:9, 1281-1287
CrossRef18
Alice O. Valencia, Mayia M. Mileva, Harry S. Dweck, Louis Rosenfeld. (1999) Specificity of glycosaminoglycan suppression of endothelin-1 production by human umbilical vein endothelial cells. Life Sciences 65:3, 279-284
CrossRef19
Laddawal Phivthong-ngam, Stefanie M. Bode-Böger, Rainer H. Böger, Michael Böhme, Ralf P. Brandes, Andreas Mügge, Jürgen C. Frölich. (1998) Dietary L-Arginine Normalizes Endothelin-Induced Vascular Contractions in Cholesterol-Fed Rabbits. Journal of Cardiovascular Pharmacology 32:2, 300-307
CrossRef20
Susan Kaufman, Yiming Deng. (1998) Adrenomedullin suppresses atrial natriuretic factor (ANF) secretion from isolated atrium. Life Sciences 63:12, 1017-1022
CrossRef21
Thomas Subkowski, Heinz Hillen, Burkhard Kröger, Martin Schmidt. (1998) Monoclonal Antibodies Against Human Endothelin-Converting Enzyme-1. Journal of Immunoassay 19:2-3, 75-93
CrossRef22
James Fink, Newton Y-T. Fan, Louis Rosenfeld, Charles T. Stier. (1998) Contribution of Endothelin to the Acute Pressor Response of L-NAME in Stroke-Prone Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology 31:4, 618-622
CrossRef23
Pankaj Sharma, Fei Lu, Andrew Rut, Morris J. Brown. (1998) Structure of Human Endothelin-2 Gene and Demonstration of Common Expression in Human Right Atrial Tissue. Biochemical and Biophysical Research Communications 245:3, 709-712
CrossRef24
C. Morin, C. Asselin, F. Boudreau, P.H. Provencher. (1998) Transcriptional Regulation of Pre-Pro-Endothelin-1 Gene by Glucocorticoids in Vascular Smooth Muscle Cells. Biochemical and Biophysical Research Communications 244:2, 583-587
CrossRef25
Terunori Mitsuma, Hiroshi Kaneko, Yoshifumi Hirooka, Shouzaburo Mori, Yuichi Mori, Koshin Adachi, Sayuri Yamamoto, Toshihiko Hayakawa, Chikara Yamaguchi, Motoaki Uruma, Nebi Rhue, Jing Ping, Tsuyoshi Nogimori. (1998) In vitro effects of endothelin-1 on somatostatin and thyrotropin-releasing hormone release from the rat stomach. Life Sciences 62:11, 1007-1012
CrossRef26
Calvert Louden, Ponnal Nambi, Carrie Branch, Kent Gossett, Mark Pullen, Scot Eustis, Henk A. Solleveld. (1998) Coronary Arterial Lesions in Dogs Treated With an Endothelin Receptor Antagonist. Journal of Cardiovascular Pharmacology 31, S384-S385
CrossRef27
Shi-wen Xu, C. P. Denton, M. R. Dashwood, D. J. Abraham, C. M. Black. (1998) Endothelin-1 Regulation of Intercellular Adhesion Molecule-1 Expression in Normal and Sclerodermal Fibroblasts. Journal of Cardiovascular Pharmacology 31, S545-S547
CrossRef28
S. Télémaque, N. Emoto, D. deWit, M. Yanagisawa. (1998) In Vivo Role of Endothelin-Converting Enzyme-1 as Examined by Adenovirus-Mediated Overexpression in Rats. Journal of Cardiovascular Pharmacology 31, S548-S550
CrossRef29
Jinshyun R. Wu-Wong, Terry J. Opgenorth. (1998) Endothelin and Isoproterenol Counter-Regulate cAMP and Mitogen-Activated Protein Kinases. Journal of Cardiovascular Pharmacology 31, S185-S191
CrossRef30
Kimberly A. Peifley, Jeffrey A. Winkles. (1998) Angiotensin II and Endothelin-1 Increase Fibroblast Growth Factor-2 mRNA Expression in Vascular Smooth Muscle Cells. Biochemical and Biophysical Research Communications 242:1, 202-208
CrossRef31
Kim Edwards Teunissen, Cornelis T. Postma, Brigit C. van Jaarsveld, Frans H.M. Derkx, Theo Thien. (1997) Endothelin and active renin levels in essential hypertension and hypertension with renal artery stenosis before and after percutaneous transluminal renal angioplasty. Journal of Hypertension 15:12, 1791-1796
CrossRef32
Sandra E. Burke, Nathan L. Lubbers, Gerard D. Gagne, Jerry L. Wessale, Brian D. Dayton, Craig D. Wegner, Terry J. Opgenorth. (1997) Selective Antagonism of the ETA Receptor Reduces Neointimal Hyperplasia After Balloon-Induced Vascular Injury in Pigs. Journal of Cardiovascular Pharmacology 30:1, 33-41
CrossRef33
M. Rita González, Eduardo Villa, Rafael García-Robles, Javier Angulo, Concepción Peiró, Jesús Marín, Carlos F. Sánchez-Ferrer. (1996) Effects of Indomethacin and Iloprost on Contraction of the Afferent Arterioles by Endothelin-1 in Juxtamedullary Nephron Preparations from Normotensive Wistar-Kyoto and Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology 28:6, 809-816
CrossRef34
João V. Vitola, Mervyn B. Forman, John P. Holsinger, Masatoshi Kawana, James B. Atkinson, Thomas Quertermous, Edwin K. Jackson, John J. Murray. (1996) Role of Endothelin in a Rabbit Model of Acute Myocardial Infarction: Effects of Receptor Antagonists. Journal of Cardiovascular Pharmacology 28:6, 774-783
CrossRef35
Annette M. Doherty. (1996) Design and discovery of nonpeptide endothelin antagonists. Drug Discovery Today 1:2, 60-70
CrossRef
